Tanayott Thaweethai (he/him) is Associate Director, Biostatistics Research and Engagement for MGH Biostatistics and an Instructor in Medicine at Harvard Medical School. He develops methods for handling missing data when conducting large observational studies using electronic health records. His research collaboration areas at Mass General include diabetes in pregnancy, clinical effectiveness of type 2 diabetes treatment, and several studies related to COVID-19. He is also lead biostatistician at the Data Resource Core for RECOVER, an NIH research initiative that seeks to understand post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID.
Dr. Thaweethai received his B.S. in Applied Mathematics – Biology from Brown University and Ph.D. in Biostatistics from Harvard University.
Dustin J. Rabideau is Associate Director, Biostatistics and Strategic Initiatives for MGH Biostatistics and an Assistant Professor of Medicine at Harvard Medical School. Dr. Rabideau’s biostatistical research focuses on robust analysis methods for cluster randomized trials and innovative methods to account for participant dropout in clinical trials. Dr. Rabideau also has extensive collaborative research experience providing statistical leadership and expertise for various investigators across MGH. His current research partnerships include the Dauten Family Center for Bipolar Treatment Innovation and the Cancer Outcomes Research and Education Program.
Dr. Rabideau earned a PhD in Biostatistics from the Harvard T.H. Chan School of Public Health. He also holds a MS and MA in Biostatistics from Harvard and a BA in Mathematics and French from SUNY Geneseo.
Andrea S. Foulkes is Director of Biostatistics at Massachusetts General Hospital, Professor of Medicine, Harvard Medical School and Professor, Department of Biostatistics, Harvard T.H. Chan School of Public Health. Under her leadership, MGH Biostatistics faculty and staff serve as lead statisticians on over 170 NIH sponsored research projects across 28 MGH divisions and departments and contribute to $489 million in research funding.
Dr. Foulkes has a 20-year active research program in statistical methods for precision medicine using high-dimensional molecular and cellular level data to inform clinical risk factors for complex disease phenotypes at the intersection of infectious disease and cardiovascular disease. Her statistical methods research is motivated and grounded in HIV/AIDS, cardiometabolic disease, inflammation and SARS-CoV-2/COVID-19 research. As PI on multiple NIH-funded awards, she is leading efforts to develop and evaluate principled statistical methods for interrogating the mechanistic underpinnings of complex diseases.
Dr. Foulkes earned a ScD in Biostatistics from Harvard University and a BA in Mathematics from Brown University.